Marcie Myers-Elder

October 10, 2023

Market wizard Dalio rummages inside the sorting hat

...Before deciding on the name PrinciplesYou, did Dalio consider Myers Bridgewater? What about Cambridge Daliotica? The company had not responded to those questions by press time....

April 23, 2021

FT Live

Commodities Asia Summit

Enabling decarbonisation in a time of disrupted trade flows

Equities

Stocks to watch: Loxo, Eli Lilly, InterContinental, Tullow, EnQuest

...complements Lilly’s existing cancer treatmentsGuggenheim But analysts played down comparisons with Bristol-Myers Squibb’s $70bn-plus deal last week to buy Celgene, which was widely seen as a rescue rather...

January 7, 2019

Markets

Stocks to watch: Celgene, Next, Apple suppliers, Vectura, Asos

...Thursday 16:10 GMT What’s happening ● Bristol-Myers Squibb slumped on fears that it was overpaying for cancer drug developer Celgene....

January 3, 2019

Due Diligence

From showtunes to sad tunes: A grocer merger meltdown Premium

...Two of DD’s favourite Alphavillians, Bryce Elder and Paul Murphy, take a characteristically humorous victory lap here....

February 21, 2019

European equities

Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche

...Roche, Bristol-Myers and Novo Nordisk also look vulnerable to accelerated adoption of biosimilars, the broker added....

May 25, 2018

FT Live

Future of Asset Management Europe

New fund firm models for Europe's resurgence

European equities

Stocks to watch: Paddy Power, Paragon, Inditex, Diageo, Aryzta

...Diageo was up on a report that the drinks maker has begun an auction of US spirits brands including Goldschlager and Myer’s Rum....

May 24, 2018

Mergers & Acquisitions

AstraZeneca climbs as Bernstein backs takeover talk

...Bristol-Myers Squibb is seen as the most likely target for Pfizer, which has telegraphed its appetite for a large transaction....

September 22, 2017

UK equities

Hopes for cancer treatment buoy AstraZeneca

...AstraZeneca jumped 4.3 per cent to £47.74 after Bristol-Myers Squibb said a combination late-stage trial of its immuno-oncology drugs had met the primary endpoint....

September 7, 2017

UK equities

Forterra and Ibstock hit records on UK housing hopes

...According to Berenberg, Roche, Merck and Bristol-Myers Squibb all have similar drugs in development “but these trials are not expected to read out until around September 2019 at the earliest, so Astra now...

May 12, 2017

Pharmaceuticals sector

Smurfit Kappa hits record high on price hopes

...AstraZeneca tumbled 3.6 per cent to £43.18 on news that Bristol-Myers-Squibb said it was no longer looking for accelerated US approval of its flagship immunotherapy drug as a first-line treatment for non-small...

January 20, 2017

UK equities

EasyJet slips amid fears of dividend cut

...Analysts pinned it to cautious guidance from Bristol-Myers Squibb around its own combination for the first-line treatment for lung cancer, due in 2018....

January 27, 2017

UK equities

AstraZeneca slides after cancer drug trial partially on hold

...The shares had hit a record high in October when Bristol-Myers Squibb said its rival immuno-oncology drug had failed a lung cancer trial....

October 27, 2016

Pharmaceuticals sector

AstraZeneca climbs on cancer drugs pipeline hopes

...Consensus forecasts are much lower because Bristol-Myers Squibb and Merck & Co are around two years ahead of AstraZeneca in the development of monotherapy cancer treatments....

September 13, 2016

UK equities

AstraZeneca climbs to a record high

...AZ climbed 1.3 per cent to £52.20 on news that Bristol-Myers Squibb’s Opdivo had failed in a trial to replace chemotherapy as the first-line treatment for lung cancer....

August 5, 2016

FT Live

Due Diligence Live

Where leaders in investment and finance meet

UK equities

AstraZeneca rises on drug pipeline hopes

...Bristol-Myers Squibb, Merck and Roche have all shown faster progress than AstraZeneca in bringing lung cancer treatments to market....

July 2, 2015

Mergers & Acquisitions

Centrica stands out as FTSE 100 falls 1%

...Allied, which was floated in June at 190p per share, said with its maiden results that Mr Pritchard would be replaced by former Bristol-Myers Squibb executive Peter Dolan....

April 28, 2015

UK equities

Water utilities boosted by takeover hopes

...AstraZeneca, up 0.9 per cent to £47.40, drifted back from £47.62 on widespread speculation that Pfizer might bid instead for Bristol-Myers Squibb....

December 5, 2014

FT AlphavilleBryce Elder

About that AstraZeneca bid defence …

...AstraZeneca bought from private equity in 2006.PT003 and PT010 were developed by Pearl Therapeutics, a California-based biotech that AstraZeneca bought in 2013.Saxagliptin/dapagliflozin were developed by Bristol-Myers...

May 6, 2014

Pharmaceuticals sector

Kazakhmys short sellers squeezed again

...AbbVie, Allergan, Amgen, Biogen, Bristol-Myers Squibb, Gilead and Pfizer could all benefit from Shire’s Irish tax domicile, it said....

June 17, 2014

Mergers & Acquisitions

Shire jumps on renewed bid speculation

...The stock has gained more than 50 per cent since being rumoured last year to have rejected an informal approach from Bristol-Myers Squibb....

April 22, 2014

UK equities

AstraZeneca climbs despite Citi’s caution

...AstraZeneca could afford to bid for Actelion as well as buying Bristol-Myers Squibb out of a diabetes joint venture, said Citi....

November 22, 2013

FT AlphavilleBryce Elder

AstraZeneca said to eye Forest Labs bid

...However, investors have expected Mr Soriot to pursue smaller deals such as buying Bristol-Myers Squibb out of an ex-US diabetes joint venture, which would cost between $4bn and $6bn....

December 3, 2013

UK equities

Shire boosted by growth hopes

...Shire has long been considered a takeover target, with the group rumoured to have rejected an opportunistic approach from Bristol-Myers Squibb earlier this year....

July 29, 2013

UK equities

Serco jumps on US contract hopes

...Shire added 1.6 per cent to £21.21 amid a reheat of takeover speculation with the drug developer rumoured to have knocked back an opportunistic approach from Bristol-Myers Squibb in the wake of poorly received...

July 2, 2013

Search Results

Viewing results 1‒25 of 38